Maze Therapeutics financials
$27.02+0.63%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $20.0M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $20.0M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | 100.0% | — | — | — | — |
| Operating income | -$48.0M | -$26.6M | -$38.1M | -$33.0M | -$36.5M | -$35.4M |
| Net income | -$44.7M | -$24.2M | -$34.6M | -$30.1M | -$33.7M | -$32.8M |
| Net margin | — | −121.0% | — | — | — | — |
| Diluted EPS | $-0.76 | $-0.45 | $-0.64 | $-0.66 | $-0.77 | $-1.15 |
| EBITDA | -$47.6M | -$26.1M | -$37.6M | -$32.4M | -$35.8M | -$34.7M |
| Operating cash flow | -$15.1M | -$39.1M | -$27.7M | -$24.6M | -$30.1M | -$29.5M |
| Free cash flow | -$15.2M | -$39.2M | -$27.8M | -$24.7M | -$30.4M | -$29.8M |
| Diluted shares | 59.0M | 53.9M | 53.7M | 45.8M | 43.8M | 28.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $202.6M | $198.8M | $189.2M | $316.8M | $264.5M | $294.4M |
| Short-term investments | $208.4M | $153.6M | $152.7M | $67.2M | $0.00 | $0.00 |
| Total debt | $39.0M | $38.8M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $531.6M | $419.7M | $397.1M | $422.1M | $303.5M | $332.8M |
| Total liabilities | $78.5M | $78.0M | $42.2M | $42.6M | $41.3M | $40.8M |
| Shareholders' equity | $453.1M | $341.7M | $355.0M | $379.4M | $262.2M | $292.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology